trending Market Intelligence /marketintelligence/en/news-insights/trending/2G5EGmClAnF6u1s5FW89Wg2 content esgSubNav
In This List

BeyondSpring drug helped prevent chemotherapy side effect in trial

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


BeyondSpring drug helped prevent chemotherapy side effect in trial

BeyondSpring Inc.'s plinabulin helped limit a chemotherapy-induced reduction in certain white blood cells, meeting the primary goal of the phase 2 portion of a phase 2/3 trial.

The study compared plinabulin to Amgen Inc.'s Neulasta, also known as pegfilgrastim, in the prevention of a side effect of docetaxel chemotherapy known as neutropenia, or an abnormally low count of neutrophil cells.

The primary goal of the trial was the number of days patients experienced severe or grade 4 neutropenia, which was measured by neutrophil count.

The initial results from the phase 2 portion will be presented at a medical meeting in San Francisco in January 2018, and the phase 3 part of the trial will begin soon, BeyondSpring said.